Acetazolamide, hypoglycemic drugs
Possible potentiation of the hypoglycemic effects
Acetylsalicylic acid, hypoglycemic drugs
Acetylsalicylic acid may increase the effect of hypoglycaemic agents
Ethinyl estradiol [1], hypoglycemic drugs ---> SmPC of [1] of eMC
The doses of insulin or hypoglycaemic drugs may need to be adjusted due to the mild diabetogenic effect of ethinylestradiol.
Hypoglycemic drugs [1], phenelzine ---> SmPC of [1] of eMC
Phenelzine may potentiate the action of hypoglycaemic agents
Hypoglycemic drugs, insulin
Possible reduction of the insulin requirements
Hypoglycemic drugs, insulin glargine/lixisenatide [2] ---> SmPC of [2] of EMA
This substance may enhance the blood-glucose-lowering effect and increase susceptibility to hypoglycaemia.
Hypoglycemic drugs, lonapegsomatropin [2] ---> SmPC of [2] of EMA
In patients with diabetes mellitus requiring therapy with a medicinal product (e.g, anti-hyperglycaemic medicinal products), the dose of insulin and/or oral hypoglycaemic medicines may require adjustment when lonapegsomatropin therapy is initiated
Hypoglycemic drugs, mecasermin [2] ---> SmPC of [2] of EMA
Doses of insulin and/or other hypoglycaemic medicinal products may need to be reduced
Hypoglycemic drugs, medroxyprogesterone
Decreased glucose tolerance and may be necessary to adjust the dosage of hypoglycaemic agent
Hypoglycemic drugs, metformin
Possible increase of hypoglycaemic effect
Hypoglycemic drugs, nadolol [2] ---> SmPC of [2] of eMC
Beta-blockade may prevent the appearance of warning signs and symptoms (e.g. tachycardia and blood pressure changes) of acute hypoglycaemia and also reduce the release of insulin in response to hyperglycaemia. It may be necessary to adjust the dose
Hypoglycemic drugs, pegvisomant [2] ---> SmPC of [2] of EMA
Patients receiving insulin or oral hypoglycaemic medicinal products may require dose reduction of these active substances due to the effect of pegvisomant on insulin sensitivity
Hypoglycemic drugs, somapacitan [2] ---> SmPC of [2] of EMA
Antihyperglycaemic treatment including insulin may require dose adjustment in case of somapacitan co-administration since somapacitan may decrease insulin sensitivity
Hypoglycemic drugs, somatrogon [2] ---> SmPC of [2] of EMA
In patients with diabetes mellitus requiring medicinal product therapy, the dose of insulin and/or oral/injectable hypoglycaemic medicinal products may require adjustment when somatrogon therapy is initiated
Hypoglycemic drugs, verteporfin [2] ---> SmPC of [2] of EMA
It is possible that concomitant use of other photosensitizing medicinal products could increase the potential for photosensitivity reactions. Caution should be exercised